New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2013
18:07 EDTVZ, CVS, AMGNSEC probes Ernst & Young on lobbying issue, Reuters says
The SEC's enforcement division and its Office of the Chief Accountant are looking in to a report that Washington Council Ernst & Young was registered as a lobbyist for several corporate audit clients including Amgen (AMGN), CVS Caremark (CVS) and Verizon Communications (VZ), says Reuters, citing people familiar with the matter. Reference Link
News For AMGN;CVS;VZ From The Last 14 Days
Check below for free stories on AMGN;CVS;VZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 22, 2014
16:25 EDTAMGNAmgen trades lower after results, first look
Subscribe for More Information
16:06 EDTAMGNAmgen sees FY14 EPS $7.90-$8.20, consensus $8.16
Subscribe for More Information
16:05 EDTAMGNAmgen reports Q1 EPS $1.87, consensus $1.94
Subscribe for More Information
15:32 EDTAMGNNotable companies reporting after market close
Subscribe for More Information
14:35 EDTAMGNEarnings Preview: Amgen's timeline for Evolocumab will be in focus
Subscribe for More Information
10:02 EDTVZBofA/Merrill's telecom analysts hold an analyst/industry conference call
Subscribe for More Information
08:01 EDTVZJacobs Engineering to acquire Verizon's FNS subsidiary
Subscribe for More Information
07:25 EDTCVSNatural E Creative Group to hold a summit
Subscribe for More Information
07:16 EDTVZiPhone sales could be hurt by fading phone subsidies, WSJ reports
Sales of Apple's (AAPL) iPhones may be further pressured as carriers make faster progress in transitioning customers away from subsidies, the Wall Street Journal reports. U.S. wireless carriers like T-Mobile US (TMUS) and AT&T (T) have been having more success than expected in moving customers to non-subsidy plans, a transition that could harm sales of expensive handsets such as the iPhone. Reference Link
April 21, 2014
14:24 EDTCVSCVS wants price competition to Gilead's hepatitis C drug, Bloomberg says
CVS said it may try to slow uptake of Gilead's new hepatitis C drug, which costs $1,000 per pill. Bloomberg cites an interview with CVS's CMO Troy Brennan.
April 20, 2014
17:11 EDTVZVerizon, AT&T may be limited in upcoming spectrum auction, WSJ says
Subscribe for More Information
April 17, 2014
07:54 EDTVZVerizon 2014 consensus estimates have upside, says Jefferies
Jefferies sees upside to the 2014 consensus estimates for Verizon given the better than expected equipment installment plans market. The firm sees 17% upside to its year-end price target of $55 and it keeps a Buy rating on Verizon.
April 15, 2014
13:49 EDTVZEarnings Preview: Analysts optimistic on Intel ahead of Q1 report
Subscribe for More Information
April 14, 2014
09:10 EDTVZT-Mobile CEO starts petition for consumers to call on peers to end overages
Subscribe for More Information
09:05 EDTVZT-Mobile abolishes consumer overages, challenges other providers to follow suit
T-Mobile (TMUS) announced a campaign to eliminate overage penalties, one of the most reviled wireless industry practices. While abolishing overages for all customers on T-Mobile consumer plans, its CEO has also laid down a challenge to the nation's largest carriers, AT&T (T), Verizon (VZ) and Sprint (S), to do the same.
07:06 EDTVZU.S. Geospatial Intelligence Foundation to hold a symposium
GEOINT 2013 Symposium, originally scheduled for October 2013, is being held in Tampa, Florida on April 14-17.
April 11, 2014
09:19 EDTVZANADIGICS ships AWC6383 dual-band ProVantage PA to Samsung
Subscribe for More Information
07:26 EDTVZTime Warner struggling to force Dodgers network on pay-TV players, LAT say
Subscribe for More Information
April 10, 2014
11:23 EDTCVSRite Aid hits 52-week high after results, sales view top estimates
Shares of retail drugstore Rite Aid (RAD) are rallying after the company's fourth quarter results and fiscal 2015 revenue outlook topped analysts' consensus estimates. WHAT'S NEW: This morning, Rite Aid reported fourth quarter adjusted earnings per share of 10c and revenue of $6.6B, compared to expectations of 4c and $6.54B, respectively. Q4 same store sales increased 2.1%. Rite Aid forecast FY15 EPS of 31c-42c, compared to the consensus of 35c. FY15 revenue was seen at $26B-$26.5B, ahead of the consensus $25.75B. FY15 same-store sales are expected by the company to be up 2.5%-4.5%. WHAT'S NOTABLE: Rite Aid also announced it has acquired RediClinic, which currently operates 30 clinics in the greater Houston, Austin and San Antonio areas. Rite Aid CEO John Standley said, “Our recent acquisitions of Health Dialog and RediClinic, our expanded partnership with McKesson and our continued commitment to investing in our store base have positioned us to transition our strategy from turnaround to growth as we more aggressively pursue opportunities to become a growing retail healthcare company.” PRICE ACTION: In late morning trading, Rite Aid rose 71c, or about 11%, to $7.11 on more than twice its average daily trading volume. Earlier in the session, the stock hit a fresh 52-week high of $7.39. Including today's advance, the stock is up approximately 300% over the past twelve months. OTHERS TO WATCH: Other retail drugstore operators include Walgreen Company (WAG) and CVS Caremark (CVS).
April 9, 2014
11:15 EDTVZT-Mobile unveils $40 monthly price plan called 'Simple Starter'
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use